GRAIL stands with policymakers and stakeholders for Medicare access framework

We believe screening individuals for many types of cancer with a multi-cancer early detection (MCED) test represents a significant opportunity to reduce the burden of cancer. However, without Congressional action, Medicare beneficiaries and their doctors may face significant delays in accessing these innovative screening tests once they are FDA-approved. Led by the American Cancer Society’s Cancer Action Network and the Prevent Cancer Foundation, a group of 52 national advocacy organizations today shared their enthusiastic support for meaningful, timely access to MCED technologies and their endorsement of advancing this legislation with its associated policy updates. GRAIL stands with the policymakers and cancer community leaders who are working to ensure, through legislation, that Medicare beneficiaries — who have the highest risk for cancer due to age — do not face unnecessary barriers to access.